Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Hold at Stifel Nicolaus

Stifel Nicolaus lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research report sent to investors on Thursday, The Fly reports. They currently have $23.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $55.00.

A number of other research firms also recently commented on SUPN. Cowen set a $50.00 target price on Supernus Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 7th. ValuEngine downgraded Supernus Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, November 6th. Jefferies Financial Group downgraded Supernus Pharmaceuticals from a buy rating to a hold rating and decreased their target price for the stock from $46.00 to $23.00 in a research report on Wednesday, November 6th. Mizuho reiterated a buy rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, August 7th. Finally, TheStreet downgraded Supernus Pharmaceuticals from a b- rating to a c+ rating in a research report on Thursday, August 29th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of Hold and an average target price of $46.50.

Shares of NASDAQ:SUPN traded up $0.13 during mid-day trading on Thursday, reaching $21.84. The stock had a trading volume of 847,513 shares, compared to its average volume of 581,150. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70. The company has a market cap of $1.53 billion, a P/E ratio of 10.65, a price-to-earnings-growth ratio of 1.02 and a beta of 1.63. Supernus Pharmaceuticals has a 1 year low of $19.35 and a 1 year high of $49.25. The business’s 50 day moving average price is $26.80 and its 200 day moving average price is $30.29.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.05). The firm had revenue of $102.14 million during the quarter, compared to analysts’ expectations of $108.70 million. Supernus Pharmaceuticals had a return on equity of 21.80% and a net margin of 25.92%. Supernus Pharmaceuticals’s quarterly revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.52 earnings per share. Analysts predict that Supernus Pharmaceuticals will post 2.14 earnings per share for the current fiscal year.

In related news, CEO Jack A. Khattar acquired 7,200 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were acquired at an average cost of $26.39 per share, for a total transaction of $190,008.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.57% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Patriot Financial Group Insurance Agency LLC purchased a new stake in Supernus Pharmaceuticals during the second quarter valued at approximately $33,000. Private Capital Group LLC grew its stake in shares of Supernus Pharmaceuticals by 108.0% during the second quarter. Private Capital Group LLC now owns 1,379 shares of the specialty pharmaceutical company’s stock valued at $83,000 after buying an additional 716 shares during the last quarter. Point72 Hong Kong Ltd grew its stake in shares of Supernus Pharmaceuticals by 324.1% during the second quarter. Point72 Hong Kong Ltd now owns 1,692 shares of the specialty pharmaceutical company’s stock valued at $56,000 after buying an additional 1,293 shares during the last quarter. First Mercantile Trust Co. grew its stake in shares of Supernus Pharmaceuticals by 31.5% during the third quarter. First Mercantile Trust Co. now owns 2,173 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 520 shares during the last quarter. Finally, Redhawk Wealth Advisors Inc. bought a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $202,000. Institutional investors and hedge funds own 99.14% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Featured Article: What is a price target?

The Fly

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.